2020 ANNUAL REPORT amfAR, The Foundation for AIDS Research OUR MISSION: amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. CONTENTS

Progress in the Face of a New Pandemic 01

Research 01

Public Policy 04

TREAT Asia 06

Public Information 07

Grants, Fellowships, and Awards 09

Research Grants, Fellowships, and Awards 09

TREAT Asia Grants and Awards 10

Financial Highlights 13

Leadership and Advisory Committees 15

Board of Trustees 15

Scientific Advisory Committee 15

Program Advisory Council 19

Management Group 19 PROGRESS IN THE FACE OF A NEW PANDEMIC

SARS-CoV-2, the virus that causes COVID-19

RESEARCH Kaufmann and his team to study why some people develop antibodies and others do not, how we can predict whether those antibodies protect against reinfection, and how long the amfAR Fund to Fight COVID-19 protection lasts. Temporarily expanding its efforts to include research on the novel coronavirus, in April 2020 amfAR established the amfAR Fund to Countdown to a Cure for AIDS Fight COVID-19, announcing its fi rst COVID grants in July. To accelerate the search for a cure, in 2015 amfAR launched its  A common and often deadly consequence of advanced COVID-19 Countdown to a Cure for AIDS initiative. To date, 87 grants totaling disease is acute kidney injury. Cells in the kidney express the more than $50 million have been awarded through the Countdown, ACE2 protein, which serves as a receptor for the virus and may supporting research conducted by 300 scientists working at underlie the kidney damage. Dr. Matthias Kretzler of the University more than 100 institutions in 16 countries. Structured to provide of Michigan, Ann Arbor, was awarded $155,650 to use a clever sustained support for a range of studies that advance both emerging technique to understand what happens in the kidney of those with and established ideas, the Countdown comprises the following COVID-19. By comparing patients receiving anti-infl ammatory components: treatment to those who were not, Dr. Kretzler aimed to develop a tool to predict who would most benefi t from this kind of treatment.  The amfAR Institute for HIV Cure Research was established in 2015 with a $20 million grant over fi ve years to the University  A second grant of $192,000 was awarded to Dr. Daniel of California, San Francisco (UCSF). Researchers at the Institute Kaufmann of the University of Montreal for a study of antibody have been laying the groundwork for a complex clinical study responses to COVID-19. Dr. Kaufmann was able to tap into the employing a three-pronged approach to eradicating HIV. A Quebec COVID-19 Biobank, established at the beginning of the therapeutic vaccine is combined with an immune adjuvant—a pandemic to collect biological samples from patients admitted drug often used to boost the effi cacy of vaccines—that has been to the hospital. These banked samples, collected from the time shown in clinical trials to have additional anti-HIV effects. The of admission through several months of follow-up, allowed Dr. third component combines two broadly neutralizing antibodies,

1 the source of much optimism in the cure fi eld for their ability not in uninfected T cells would be an important step toward a cure. only to kill viruses that are produced by infected cells, but also to Magnet grantee Dr. Ya-Chi Ho has collected vast amounts of data direct the immune system to kill the very cells producing those on the activity of over 133,000 T cells, including rare reservoir viruses. In August 2020, the trial got underway when the fi rst cells, across seven people living with HIV. With the help of injection was given to the fi rst participant. bioinformatician Dr. David van Dijk, the team is building machine- learning tools to identify mediators of T cell expansion that affect  ARCHE, the amfAR Research Consortium on HIV Eradication, reservoir cells specifi cally. supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. For several Collaborating with data scientists Drs. Doron Betel and Friederike years, amfAR’s ARCHE-GT consortium has been designing and Dundar, Dr. Brad Jones aims to identify, using public and private fi ne-tuning three gene therapy approaches to curing HIV that datasets, differences between reservoir cells that survived attack could be delivered in vivo—directly to the patient. by the immune system and those that were susceptible. Then the researchers will analyze cancer datasets to determine whether One approach involves the generation of chimeric antigen those protective factors identifi ed in HIV are also present in receptor (CAR) stem cells that are designed specifi cally to kill cancer—a disease that may have FDA-approved drugs to target virus-infected cells. A second is to spur liver cells to produce HIV- those factors. specifi c antibodies. The third is to deliver an enzyme that would edit the virus out of infected cells. Each of these three tools is now By understanding exactly where HIV inserts itself in our genome, ready to be tested in combination. researchers can make inferences about how location may predict latency. Dr. Sharon Lewin, a world-renowned HIV cure researcher, In February 2020, Dr. Hildegard Büning of Hannover Medical has teamed up with Dr. Daniel Cameron, a former software School, Germany, was awarded $1.65 million for a preclinical developer turned academic bioinformatician, to develop a data study to test their effectiveness. This complex gene therapy science mapping pipeline to chart the hard-to-reach areas of our study will provide vital signposts informing further curative gene genome. Using over 600GB of cloud computing memory and therapy studies. mining 30 public and private datasets, the researchers aim to gain a more complete understanding of what insertion site means for  Uniting data scientists with HIV researchers, one-year Magnet HIV latency—and ultimately cure. Grants of up to $150,000 are harnessing advances in machine

learning algorithms to fi nd patterns in the vast trove of data  Synergy Grants capitalize on unforeseen possibilities for researchers have amassed over the past decade. Already a collaboration and enable us to add new study arms onto existing critical component of the success of precision medicine, machine amfAR grants. In February 2020, amfAR awarded $50,000 to Dr. learning is able to identify patterns in health and disease that we Jonathan Li of The Brigham and Women’s Hospital in Boston. wouldn’t know to look for. In February 2020, amfAR awarded In 2019, amfAR launched Project PTC, the largest study to grants totaling about $600,000 to research teams in the U.S., date aimed at discovering the underpinnings of post-treatment Australia, and Brazil. control—viral control in the absence of antiretroviral therapy (ART). Led by Dr. Li, one of the world’s leading PTC researchers, The HIV reservoir may expand when infected T cells grow in the team has been using cutting-edge tools to explore immune number to fi ght invading pathogens. Identifying how to limit control and viral dynamics. The new grant recruited Dr. Michael expansion in reservoir cells while maintaining normal expansion Seaman, an expert in HIV antibody responses at Harvard Medical School. This additional expertise could help determine whether antibodies help shape the ability of PTCs to control virus once they stop taking ART. Discovering what leads to post-treatment control in these rare individuals could help in designing methods to achieve durable ART-free control in all people living with HIV.

Mathilde Krim Fellowships in Basic Biomedical Research

These fellowships support bright young scientists advancing innovative solutions to HIV/AIDS. In December 2019, amfAR announced two new Krim Fellows: Dr. Maolin Lu of Yale University in New Haven, CT, and Dr. Shaheed Abdulhaqq, of Oregon Health and Science University in Portland, OR. Each fellow is awarded approximately $150,000 over two years.

COVID-19 Pause

Due to the COVID-19 pandemic, in March 2020 amfAR temporarily paused its ongoing HIV research grants with the exception of one amfAR grantee Dr. Brad Jones

2 EXPLORER Imaging by Dr. Timothy Henrich: (Left to right) CT scan, PET overlaid on CT, and PET image. Scale at right shows virus signal intensity.

grant funded by the FAIR Foundation. The pause ended on July 1, HIV Cure Summit 2020, for a clinical trial at the amfAR Institute for HIV Cure Research In November 2019, amfAR held its sixth annual HIV Cure Summit in San Francisco, and October 1 for other paused research. at the University of California, San Francisco (UCSF), where the amfAR Institute for HIV Cure Research is based. Leading amfAR- Published Research funded cure researchers detailed their progress and discussed the scientifi c challenges that continue to stand in the way of a cure. Dr. Research studies make the greatest impact on the HIV fi eld and Rachel Rutishauser, for example, outlined the pioneering clinical on the broader scientifi c community when they are published in trial at the Institute that will test a combination approach to curing scientifi c journals. In FY2020, 80 scientifi c publications resulted HIV (see page 1). from amfAR-funded research. Examples include: Dr. Rowena Johnston, amfAR Vice President and Director  Seeing Is Believing: Nuclear Imaging of HIV Persistence of Research, discussed “societies of research,” displaying a In Frontiers in Immunology, Dr. Timothy Henrich of the amfAR visualization tool to show how in recent years HIV researchers are Institute for HIV Cure Research and colleagues outlined a cutting- collaborating more than ever before. Speaking with Dr. Johnston, edge technique using the only EXPLORER PET scanner currently Loreen Willenberg, the “San Francisco patient,” shared her inspiring operational in the U.S. to visualize the places where HIV resides in personal story, from her HIV diagnosis in 1992 to recognition by her host tissue cells. The machine is able to produce images that are doctors that she was somehow able to maintain undetectable viral approximately 40 times more sensitive than current technology levels without ever taking ART, to being an invaluable participant in in a fraction of the time. The technology may help researchers HIV studies for over a decade. identify which tissues are responsible for HIV resurgence following treatment interruption as part of a cure intervention. Discussing post-treatment control of HIV, Drs. Peter Hunt of UCSF and Marcella Flores of amfAR outlined efforts to study the rare  Attacking Latent HIV with Convertible CAR T Cells, a Highly individuals—post-treatment controllers—who are able to naturally Adaptable Killing Platform control their virus after stopping ART. A better understanding of In the prestigious journal Cell, members of the amfAR Institute how these individuals are able to do so could help researchers for HIV Cure Research reported the development of a new type induce post-treatment control in other people living with HIV. of CAR T cell—one that can keep up with HIV’s ever mutating envelope. Convertible CAR T cells can target multiple strains The Summit also featured a range of perspectives from members of HIV without the need to manufacture as many different CAR of the community advisory board for the amfAR Institute and other T cells as there are strains. Harnessing the ability of this new community leaders. platform to selectively kill HIV-infected cells, researchers may be able to develop more effective cure strategies in which latency- reversing agents reactivate latent HIV.

3 PUBLIC POLICY COVID-19. The study generated signifi cant national media attention. Published in Annals of Epidemiology in July 2020, it has been cited in more than 100 publications including the New England Journal of Informed by thorough research and analysis, amfAR is a highly Medicine and JAMA. respected advocate of rational and compassionate HIV/AIDS- related public policy. The Foundation is engaged in efforts to secure Also in July, a study by a multi-institutional team led by researchers necessary increases in funding for HIV/AIDS research and global at The George Washington University found that factors linked to HIV/AIDS programs, expand access to treatment and care for structural racism put Latino communities nationwide at high risk of marginalized populations, advocate harm reduction policies aimed COVID-19. amfAR’s Greg Millett was senior author on the study. The at reducing the spread of HIV and hepatitis C (HCV) among people researchers detailed contributing factors including crowded housing, who inject drugs, and protect the civil rights of all people affected by air pollution and jobs in the meatpacking and poultry industry. The or vulnerable to HIV/AIDS. fi rst national analysis of COVID deaths and cases among this group, it confi rmed previous reports that Latinos were particularly hard hit by the virus. Ending the Domestic HIV Epidemic In August, an amfAR study showed that disproportionately white In 2019, President Trump announced a plan to end HIV counties in the U.S. had consistently lower rates of COVID-19 transmissions in the U.S. by 2030. The Ending the HIV Epidemic and HIV. Residential segregation, structural racism, and social (EHE) initiative aims to reduce HIV infections by 75% in fi ve determinants of health were noted as key factors driving diagnoses years, and by 90% in ten years. In 2019, amfAR launched a free in nonwhite communities. With schools reopening in some states, interactive database (ehe.amfar.org) to help policymakers, public the amfAR study suggested that comparatively higher COVID-19 health offi cials, advocates, and other stakeholders understand diagnoses in non-white counties placed youth and adults in those the opportunities and challenges across EHE jurisdictions. The counties at greater risk for infection. EHE database includes demographic, policy, and service provider information, and epidemiological indicators. As a companion resource for these studies on disparities, amfAR launched a new data dashboard tracking COVID-19 cases and In October 2019, amfAR published Context Matters: Ending the HIV diagnoses in U.S. counties with a large proportion of racial/ethnic Epidemic Among Latinx, an infographic showing how lack of access minorities. to healthcare, along with the Trump administration’s anti-immigrant rhetoric and policies, make it unlikely that the EHE initiative will succeed. A second infographic depicted the stark racial disparities Context Matters: Ending the HIV Epidemic Among Latinx in the epidemiology of HIV and access to care in the U.S. The federal government’s Ending the HIV Epidemic (EHE) Non-citizens and undocumented individuals will be less likely to seek testing, prevention, or treatment services if they fear deportation and plan has the goal of reducing new HIV infections by 90% In February, amfAR Vice President and Director of Public Policy arrest, or loss of the opportunity to someday become citizens. And in the next 10 years. This goal will not be met without their families and communities may also be less likely to access Greg Millett penned an op-ed for Healio’s Infectious Disease eliminating disparities in access to services in the Latinx services in order to protect themselves and undocumented people in their community. community. The current administration’s anti-immigrant News that argued for HIV prevention programs tailored to Black These policies directly undermine any efforts in the EHE plan to rhetoric and policies make this unlikely to happen. improve access to services among the Latinx community. Americans. This was followed by a Millett op-ed in The Hill on progress and setbacks a year into the EHE initiative. Demographics What’s Helping?

Percent of population that is Latinx Ending the HIV Epidemic Since the implementation of the Affordable Care Act (ACA) in 2010, (EHE) plan millions of Americans including people living with HIV have benefi ted • 90% targeted decrease in HIV infections by 2030 18.3% 5.6% 31.1% • 48 counties, plus Washington, D.C. and San Juan, P.R. from expanded access to healthcare. On the tenth anniversary of • 7 states Nationally 7 states targeted Counties targeted the ACA being signed into law, in March 2020, amfAR published a under EHE plan under EHE plan report showing with charts and graphics the progress that has been Access What’s Not? Percent of people without health insurance (under 65) Several administration actions directly undercut any efforts in the EHE achieved by the ACA and what could be lost due to Congress and 25 plan to improve access to services among the Latinx community. 21.1% 21.3% President Trump undermining the policy. In particular, the report 20 Demonization of 15 immigrants and Latinx showed how the ACA could benefi t Trump’s effort to end the HIV 14.4% 10 12.2% Leads to increased stigma, real and feared, preventing groups from accessing services epidemic through his EHE plan. 5

0 National Latinx Total, Latinx, Fear of arrest and deportation EHE Counties EHE Counties Prevents Latinx, especially the undocumented and their families, from accessing services The COVID-19 Pandemic Epidemiology New diagnoses among Latinx men who have sex with men (MSM), 25-34 Public charge rule (% increase) Drives noncitizens to avoid using public bene ts

In May 2020, amfAR released study results that were among the fi rst 35 32.7% including health services to quantify disparities in impacts of the coronavirus pandemic. The 30 25 Federal immigration restrictions study revealed that disproportionately Black counties—representing 20 Restrictions prevent immigrants who do not have 15 health insurance from entering legally about one in fi ve U.S. counties—accounted for 52% and 58% of 10 5 COVID-19 cases and deaths, respectively. It also countered the 0 2010 2011 2012 2013 2014 2015 2016 2017 narrative that underlying health conditions were responsible for disparate rates of SARS-CoV-2 diagnoses among Black Americans. Instead, social factors such as high rates of uninsured and crowded To see additional data about various policies across EHE locales, go to http://ehe.amfar.org One of a series of infographics illustrating priority issues for amfAR’s households in Black counties were responsible for greater rates of Pubic Policy Offi ce.

4 Also in August, amfAR published an issue brief on gender-based In October 2019, amfAR published a 20-page report titled Data violence (GBV) in South Africa during the coronavirus pandemic. Watch: Data Accessibility from Global Funders of HIV, TB and The analysis found signifi cant barriers to service availability Malaria Programming. The report assessed the adequacy of and called for government action and resources to be directed information regarding who is being funded in a given community, to ensure reliable access to GBV services for the duration of what they have been funded to do, and whether they have delivered COVID-19 and beyond. as contracted. amfAR also published several op-eds early in the pandemic. In February 2020, amfAR Senior Policy and Medical Advisor Dr. AIDS 2020 Susan Blumenthal penned an op-ed for The Hill outlining fi ve amfAR’s Public Policy Offi ce participated in the biennial International ways to prepare for the coronavirus. In March she wrote for The AIDS Conference—the premier global meeting for the HIV fi eld—July Advocate on the essential lessons from the AIDS epidemic that 6-10. Delegates came together virtually to hear about and discuss could be applied to the COVID-19 crisis, followed by two op-eds the latest HIV research fi ndings and policy issues, and intersections in April: one in Thrive Global argued that young people held the with the coronavirus. key to “fl attening the curve,” and the other, for CNN, made the case for studying the effects of COVID on women. Public Policy Director Greg Millett delivered an opening plenary talk that contextualized 40 years of disparities throughout the HIV pandemic, and joined a live Q&A session with Dr. Linda-Gail Bekker HIV and the Opioid Epidemic of the Desmond Tutu HIV Centre at the University of Cape Town, amfAR’s Opioid & Health Indicators Database (opioid.amfar.org) is former president of the International AIDS Society. a free web platform designed to support lawmakers, communities, and advocates in making informed decisions about the opioid amfAR’s Deputy Director of Public Policy Brian Honermann epidemic and its impact on HIV and hepatitis C. It provides local presented at a virtual community workshop that focused on to national statistics using reliable data sources on new HIV and the effective use of data tools to drive impactful change in the hepatitis C infections, opioid use and overdose death rates, and HIV response. And Policy Associate Jennifer Sherwood gave a the availability of services like drug treatment programs and symposium talk on whether current approaches to collecting data syringe exchange services. capture the full impact of HIV on women. The conference featured many talks on the intersection of HIV Advocating on the Global Stage and COVID-19. Greg Millett joined Merck Vice President of Social Innovation Carmen Villar for a “fi reside chat” to discuss a paper In November 2019, amfAR published an issue brief outlining the Millett co-authored assessing the differential impacts of COVID-19 impacts of the “global gag rule” for the Global Fund to Fight AIDS, on black communities. Millett also joined Chris Collins of Friends Tuberculosis and Malaria. Reinstated and expanded by President of the Global Fight and others in a session titled How did they do Trump in 2017 [and subsequently rescinded by the Biden it? What successful communities can teach all of us about making administration], the policy restricted non-U.S.-based or foreign dramatic progress against HIV epidemics and what this means in NGOs from receiving American fi nancial aid if they perform, the age of COVID. The session was a one-year follow-up to a report counsel on, or refer for abortion, or advocate for its liberalization co-authored by amfAR, AVAC and Friends of the Global Fight titled outside of limited exceptions. The issue brief concluded that Translating Progress into Success to End the AIDS Epidemic. the policy was linked to “disruptions in HIV programming—including basic HIV prevention services such as condom distribution, HIV testing, and voluntary medical male circumcision programming to prevent HIV.” amfAR maintains the PEPFAR Monitoring, Evaluation, and Reporting database (mer.amfar.org). Launched in 2018, the database enables policymakers, public health offi cials, advocates, and other stakeholders to access a wide range of programmatic data on PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) and includes downloadable PDFs, maps, data visualizations, and district-level data. The database complements amfAR’s PEPFAR database (copsdata.amfar.org), which highlights planned funding by program area, country and organization for each year that amfAR VP and Director of Public Policy Greg Millett delivered an opening plenary address at AIDS has been publicly released. 2020, the virtual International AIDS Conference.

5 TREAT ASIA amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of treatments for HIV and its co-infections to adults and children across the Asia-Pacific through research, education, and advocacy. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 33 publications in peer-reviewed medical journals in 2020.

Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/ AIDS, which now includes anonymous data from nearly 10,000 patients at 21 clinical sites in 12 countries. The TREAT Asia HIV Observational Database (TAHOD) gathers TREAT Asia’s regional network spans more than 50 research institutions and information to inform the development community organizations in 13 countries across the Asia-Pacific region. of more effective research and treatment programs and helps define treatment and implementation science research in the Asia-Pacific region. standards specific to HIV/AIDS in Asia. The TAHOD-LITE database, The objective of the CHIMERA program (Capacity development an extension of TAHOD, contains data from over 37,000 HIV- for HIV and mental health research in Asia) is to address the positive patients across ten TREAT Asia network sites and aims to dual and interlinked burdens of HIV and mental health. Co-led by increase the scope of adult data collection by gathering a subset of Principal Investigators Dr. Annette Sohn, amfAR vice president core variables from all HIV-infected patients who have sought care and director of TREAT Asia, and Dr. Milton Wainberg, professor of at selected TAHOD sites. clinical psychiatry at Columbia University and the New York State Psychiatric Institute, the program aims to build a team within the A Global Collaboration Asia-Pacific with the capacity to lead regional HIV-mental health- implementation science research that will inform public health policy In partnership with the Kirby Institute at the University of New and improve the quality of clinical care for people living with HIV. South Wales, TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (IeDEA), The program is nested within the IeDEA (see above) Asia-Pacific a global collaboration established by the U.S. National Institute of regional research network that TREAT Asia directs. CHIMERA Allergy and Infectious Diseases. creates the opportunity to bring together stellar training faculty from academic centers and public health and development agencies Improving Care for Children within the region and across the world, and builds on existing NIH- funded mental health research being conducted through IeDEA The TREAT Asia Pediatric HIV Observational Database is a regional Asia-Pacific. pediatric HIV study set up by TREAT Asia in 2006. It was modeled on the adult database and includes data from more than 7,400 In February 2020, a workshop for CHIMERA fellows was held children and adolescents at 17 clinical sites in Cambodia, India, in Bangkok, covering implementation science frameworks and Indonesia, Malaysia, Thailand, and Vietnam. study designs, informatics for research and public health, and the responsible conduct of research. Fellows also met with TREAT Asia and faculty to discuss their pilot research proposals. Integrating HIV, Mental Health, and Implementation Science Research The COVID-19 Pandemic In 2019, the U.S. National Institutes of Health awarded a five- year, $1.4 million grant to TREAT Asia and Columbia University to In April 2020, TREAT Asia led the submission of a letter to the establish an innovative platform for integrating HIV, mental health, Regional Directors of World Health Organization (WHO) South-East

6 Asia and Western-Pacific. Signed by 32 regional and national civil opportunities for local clinicians, students, and researchers to society organizations, the letter called for WHO to play a greater role submit abstracts for presentation. in ensuring continuity of HIV-related healthcare services during the COVID-19 public health emergency in the Asia-Pacific. The 2019 TREAT Asia Annual Network Meeting was held in October 2019 in Bangkok, Thailand, where adult and pediatric investigators, TREAT Asia is collaborating with the Institute of HIV Research and donors, and program partners gathered to review progress on the Innovation (IHRI), Thai Red Cross AIDS Research Center (TRC- network’s research agenda, hear about regional HIV-related policy ARC) laboratory, and the NIH Vaccine Research Center to conduct priorities, and plan for future initiatives. SARS-CoV-2 serologic assays of Thai adults taking and not taking antiretroviral drugs for pre-exposure prophylaxis and treatment of HIV. In September 2020, more than 1,800 samples were sent to the National Institutes of Health. THE GMT INITIATIVE Throughout the year, TREAT Asia participated in various meetings held virtually with organizations and community members from countries throughout the Asia-Pacific region to navigate the impacts The two implementation science studies being supported by of COVID-19 on critical HIV and hepatitis services and initiatives. amfAR’s GMT Initiative came to an end in 2019, bringing the initiative to a close. The three-year projects, in Myanmar and Thailand, were aimed at determining the most effective ways of Helping Adolescents Transition to Adult Care engaging gay men, other men who have sex with men (MSM), and More than one in four new HIV infections in the Asia-Pacific occur transgender individuals (collectively, GMT) at risk of infection or in young people aged 15–24 years. Continuing its commitment to already living with HIV. The goal was to help those who were HIV- helping adolescents transition to adult care, in 2019 TREAT Asia negative stay uninfected, and help HIV-positive individuals to begin initiated plans for a study of adolescents and young adults living and remain on treatment. A third project, in Peru, ended in 2018. with HIV. A total of 75 HIV-disclosed adolescents with HIV were enrolled from three participating sites in Thailand and the Philippines for initial and 12-month follow-up assessments. Critical outcomes including viral suppression, treatment adherence, pregnancy, and PUBLIC INFORMATION mortality will be assessed.

amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/ AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

The COVID-19 Pandemic

When the COVID-19 crisis emerged in early 2020, amfAR dedicated a section of its website to information on the coronavirus and the intersection of HIV and COVID-19 in particular. The section featured resources for people living with HIV and news of the latest

studies as more and more data emerged. Audiovisual content AIDS 2020 included a video announcement of the launch of the amfAR Fund Asia had a strong presence at the 23rd International AIDS Society to Fight COVID-19 and a series of interviews featuring amfAR Conference (AIDS 2020) held virtually in July. TREAT Asia Director VP and Director of Research Dr. Rowena Johnston and amfAR Dr. Annette Sohn moderated a prime session Q&A on pediatric HIV grantees who had quickly pivoted to research on COVID-19. These along with Martina Penazzato of the World Health Organization. Dr. informative interviews covered topics such as testing, vaccine Sohn also spoke at a workshop addressing the essential skill for development, experimental treatments, and COVID in children, and early-career HIV researchers of writing and successfully submitting garnered tens of thousands of views. scientific papers to peer-reviewed journals. Numerous TREAT Asia partner investigators and affiliates also gave poster presentations at Educational Materials the conference. amfAR‘s newsletter Innovations is published twice a year and TREAT Asia also participated in the fifth Asia Pacific AIDS & Co- distributed to more than 40,000 people, while a monthly email Infections Conference (APACC), held virtually in October 2020. newsletter reaches approximately 10,000 readers. APACC is a regional-level HIV research conference that provides

7 Media Outreach

In FY2020, amfAR continued to work closely with the media to raise the profi le of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR— many of which included interviews with staff—were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, Fast Company, The Atlantic, Vice, HuffPost, Business Insider, U.S. News & World Report, Vox, Vanity Fair, New York Magazine, People, Gizmodo, The Verge, The Advocate, Politico, The Hill, Reuters, Associated Press, CBS News, BBC News, CNN, NPR, MSNBC, ABC News, and NBC News. As the COVID-19 pandemic evolved, amfAR explored emerging research priorities through a series of video interviews with leading scientists. Celebrity Support

The Foundation’s websites—www.amfar.org and www. amfAR’s public awareness efforts are greatly enhanced by the curecountdown.org—feature news, interviews, and original articles committed support of public fi gures who lend their voices and covering HIV research, policy, the global epidemic, and amfAR donate their time, talents, and resources to help sustain the programs and activities. The websites attract a combined average Foundation’s mission. Support of amfAR by prominent public of 46,000 visitors per month. amfAR also creates and distributes fi gures began with the late Dame Elizabeth Taylor, amfAR’s reports, press releases, and updates on major HIV/AIDS issues Founding International Chairman, and others have followed in and conducts public service advertising campaigns that have been her footsteps. instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public. amfAR is profoundly grateful for the continuing support of celebrities from all over the world, including Iman, James Corden, amfAR’s Public Information team also works closely with the Public Tom Ford, Cheyenne Jackson, Paris Jackson, Heidi Klum, Policy Offi ce (see above) to produce a wide range of issue briefs, Katy Perry, Julia Roberts, Alan Cumming, Christina Aguilera, facts sheets, infographics, and reports. Gwyneth Paltrow, Lily Aldridge, Adrien Brody, Andy Cohen, Diplo, Padma Lakshmi, Billy Porter, Zac Posen, Laid Ribeiro, Coco Rocha, Epic Voices Carine Roitfeld, Amber Valletta, Virgil Abloh, Alessandra Ambrosio, Peter Dundas, Ashley amfAR’s Epic Voices, an online video series that aims to Graham, Winnie Harlow, reenergize the response to HIV among millennial and LGBTQ Miranda Kerr, communities, continued to generate signifi cant engagement Karlie Kloss, Karolina in 2020. A ten-episode Instagram IGTV series featuring the Kurkova, Adriana Lima, videos received more than 7,500 views. The series profi les HIV Jasmine Sanders, activists across the country who share their unique journeys, Shanina Shaik, Irina their insights on living with HIV, and the bold steps they have Shayk, Joan Smalls, taken in the fi ght against the epidemic. Lara Stone, Jasmine Tookes, and Diane Social Media von Fürstenberg.

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds educational and fundraising news and information to its amfAR honored Facebook page and Twitter and Instagram feeds. amfAR has legendary model and entrepreneur Iman at the over 76,000 likes on Facebook, more than 43,000 Twitter 2020 New York Gala for followers, and 159,000 Instagram followers. her contributions to the fi ght against AIDS.

8 GRANTS / FELLOWSHIPS / AWARDS

2020 RESEARCH IMPACT GRANTS: GAINING INSIGHTS SYNERGY GRANT: GAINING INSIGHTS FROM THE CLINIC FROM THE CLINIC GRANTS, FELLOWSHIPS Identification of integrative multi-omics signature Humoral Immune Response in HIV Rebound predictive of HIV replication control without the Jonathan Li, MD, MMSc The Brigham and Women’s Hospital, Inc. All projects below were awarded funding use of ART Simone Gonçalves da Fonseca, PhD Boston, MA during the period October 1, 2019 through Fundação de Apoio à Pesquisa (FUNAPE) $50,000 September 30, 2020. Goiânia, Brazil $63,0401 1Supported with funds provided by the FAIR Deep learning methods to personalize antibody MATHILDE KRIM FELLOWSHIPS IN Foundation therapeutics for delaying viral rebound after BIOMEDICAL RESEARCH cessation of ART Hillel Haim, MD, PhD Harnessing Universal MHC-E-Restricted T cell University of Iowa Receptors for HIV Cure amfAR FUND TO FIGHT COVID-19 Iowa City, IA Shaheed Abdulhaqq, PhD $149,995 Oregon Health and Science University Predictors of SARS-CoV-2 antibody responses Portland, OR after severe COVID The driving force of the clonally expanding HIV-1- $150,000 Daniel Kaufmann, MD infected cells - a single-cell approach Université de Montréal, Centre de Recherche du Ya-Chi Ho, MD, PhD HIV-1 fusion studied by parallel single molecule CHUM Yale University FRET and cryo-electron tomography Montreal, Canada New Haven, CT Maolin Lu, PhD $209,712 $150,000 Yale University New Haven, CT Protecting epithelial cell organ from COVID-19 Integrating Transcriptomic and Proviral Integration $150,000 attack Site Data-Sets to Define Mechanisms of ‘CTL Matthias Kretzler, MD, PhD Resistance’ in Reservoir The University of Michigan Brad Jones, PhD Ann Arbor, MI Weill Medical College of Cornell University $155,650 New York, NY $150,000 amfAR RESEARCH CONSORTIUM A hidden reservoir? An in-depth analysis of HIV ON HIV ERADICATION (ARCHE): integration across the entire human genome Sharon Lewin, FRACP, PhD GENE THERAPY University of Melbourne Preclinical in vivo non-human primate study of Melbourne, Australia combined treatment strategies $149,999 Hildegard Büning, PhD Hannover Medical School Hannover, Germany $1,558,021

97 Melbourne Sexual Health Centre Sydney Sexual Health Centre, Sydney Hospital 2020 TREAT ASIA Carlton Sydney GRANTS AND AWARDS Richard Teague, MBBS (Monash Uni), FRACGP, Rick Varma, MBBS, MRCP FRAChSHM $6,3001 $5,4751 Taylor Square Private Clinic All projects listed below were awarded Monash Health - Clayton Sydney funding for the period October 1, 2019, Clayton Robert Finlayson, MBBS, (Syd) Di FAChSHM, through September 30, 2020. Ian Woolley, MBBS, FRACP DipVen, MB BS $7,5001 $6,5251

1Supported by National Institutes of Health federal D.A. Ellis Pty., Ltd. Clinic 468, HNE Sexual Health, Hunter New Coffs Harbour England Local Health District award number U01AI069907, with funds from David Ellis, MBBS Tamworth NEMSC the National Institute of Allergy and Infectious $450 Nathan Ryder, MD Diseases, the Eunice Kennedy Shriver National $1,650 Northern Territory of Australia Dept of Health Institute of Child Health and Human Development, through Top End Health Service Illawarra Shoalhaven Local Health District the National Cancer Institute, the National Institute Darwin Warrawong of Mental Health, the National Institute on Drug Manoji Gunathilake, MBBS, MD, FAChSHM Katherine Brown, MD Abuse, the National Heart, Lung, and Blood $2,100 $1,725 Institute, the National Institute on Alcohol Abuse Nepean Blue Mountains Local Health District, and Alcoholism, the National Institute of Diabetes Blue Mountains Sexual Health and HIV Clinic CAMBODIA and Digestive and Kidney Diseases, and the Katoomba Fogarty International Center Eva Jackson, MBBS, FAChSHM $1,950 National Center for HIV/AIDS, Dermatology 2 & STDS / Cambodia National Institute of Supported by National Institutes of Health federal Nepean Blue Mountains Local Health District, Public Health award number D43TW011302, funded by the Nepean Sexual Health Clinic Phnom Penh Fogarty International Center and the National Kingswood Ly Penh Sun, MD, MSc Institute of Mental Health Eva Jackson, MBBS, FAChSHM TAHOD Low Intensity Transfer (TAHOD-LITE) $1,950 $9,5001 3Supported with funds provided by Life Ball. Sexual Health and AIDS Services (SHAIDS) TREAT Asia HIV Observational Database (TAHOD) Lismore $20,8001 David Smith, MBBS, DipVen, FAChSHM, AUSTRALIA GrapDip BA TREAT Asia Pediatric HIV Observational Database $7,5001 (TApHOD) Site 1 University of New South Wales $25,000 Sydney Victorian HIV Service, Infectious Diseases Matthew G. Law, PhD Department, The Alfred Hospital IeDEA Asia-Pacific Research Collaboration: Data Melbourne CHINA Management and Analysis Center Jennifer Hoy, MBBS 1 $552,5201 $7,500 Queen Elizabeth Hospital Hong Kong AUSTRALIAN HIV OBSERVATIONAL DATABASE Northside Clinic (Vic) Pty Ltd Man Po Lee, MBBS (AHOD) SITES North Fitzroy TAHOD Low Intensity Transfer (TAHOD LITE) Richard Moore, MBBS $7,5001 1 O’Brien Street Practice $7,500 TREAT Asia HIV Observational Database (TAHOD) Adelaide Prahran Market Clinic Pty Ltd William Donohue, MBBS including NCD Data Prahran $22,8001 $1,275 Norman Roth, MBBS, FAChSHM 1 Sunshine Coast Hospital and Health Service $7,350 Birtinya East Sydney Doctors INDIA David Sowden, MBBS Sydney 1 $7,500 David Baker, MB, ChB, Dip Med The Voluntary Health Services Chennai Sexual Health and HIV Service In Metro North (Sexual Health), DCH $7,5001 Naglingeswaran Kumarasamy, MD, MBBS, PhD Brisbane TAHOD Low Intensity Transfer (TAHOD-LITE) Diane Rowling, MBBS, MTH, F(PHM), RACP, Holdsworth House Medical Practice $15,000 (funding awarded in 2020 for project FACSHM Sydney years 14 & 15) 1 $7,500 Mark Bloch, MD $7,5001 TREAT Asia HIV Observational Database (TAHOD) Cairns Sexual Health Service including NCD Data Cairns North St. Vincent’s Hospital Sydney Limited $22,8001 Darren Russell, MD Sydney 1 $7,500 Andrew Carr, MD TREAT Asia Pediatric HIV Observational Database $7,5001 (TApHOD) RPA Sexual Health Clinic $7,5001 Camperdown David Templeton, PhD $7,4251

10 BJ Medical College & Sassoon General Hospitals Hospital Raja Perempuan Zainab II SOUTH KOREA Pune Kota Bharu Aarti Kinikar, MD, DCH, DNB, MRCP-Pediatrics UK Nik Khairulddin Nik Yusoff, MD Yonsei University College of Medicine TREAT Asia Pediatric HIV Observational Database TREAT Asia Pediatric HIV Observational Seoul (TApHOD) Database (TApHOD) Jun Yong Choi, MD, PhD $7,5001 $7,5001 TAHOD Low Intensity Transfer (TAHOD-LITE) $6,0001 Shashikala Sangle, MD Hospital Likas IeDEA Sentinel Research Network (SRN)—Asia- Kota Kinabalu TREAT Asia HIV Observational Database (TAHOD) Pacific Fong Siew Moy, MBBS including NCD Data $113,7651 TREAT Asia Pediatric HIV Observational $17,6401 Database (TApHOD) TREAT Asia HIV Observational Database (TAHOD) $7,5001 including NCD Data TAIWAN $21,0851 Pediatric Institute, Hospital Kuala Lumpur Kuala Lumpur Taipei Veterans General Hospital Institute of Infectious Diseases Thahira Mohamed, MBBS Taipei City Pune TREAT Asia Pediatric HIV Observational Database Yu-Jiun Chan, MD Sanjay Pujari, MD, AAHIVS, MBBS (TApHOD) TREAT Asia HIV Observational Database (TAHOD) TAHOD Low Intensity Transfer (TAHOD-LITE) $7,5001 including NCD Data $9,500 $24,8001 University of Malaya TREAT Asia HIV Observational Database (TAHOD) Kuala Lumpur including NCD Data Reena Rajasuriar, PhD 1 $22,300 Capacity development for HIV and mental health THAILAND research in Asia (CHIMERA) Chulalongkorn University $6,048 Bangkok INDONESIA University of Malaya Medical Center Suvaporn Anugulruengkitt, MD Sanglah Hospital, Udayana University School of Kuala Lumpur Study on Pregnancy and Birth Outcomes among Medicine Raja Iskandar Shah Raja Azwa, MBBS Youth living with HIV in Asia Denpasar Substance use, Stigma, Depression and Disability $1,5001 Tuti Parwati Merati, MD among Adults with HIV in Asia (S2D2) 1 Thanyawee Puthanakit, MD TAHOD Low Intensity Transfer (TAHOD-LITE) $2,514 Adolescent and Young Adult network of IeDEA $8,0001 TREAT Asia HIV Observational Database (TAHOD) (AYANI) Study Site TREAT Asia HIV Observational Database (TAHOD) including NCD Data $17,1461 1 including NCD Data $22,300 TREAT Asia Pediatric HIV Observational Database $22,8001 Sungai Buloh Hospital (TApHOD) Ketut Dewi Kumara Wati, MD Sungai Buloh $15,0001 TREAT Asia Pediatric HIV Observational Yasmin Mohamed Gani, MD HIV-NAT / Thai Red Cross AIDS Research Centre Database (TApHOD) TREAT Asia HIV Observational Database (TAHOD) 1 Bangkok $7,500 including NCD Data Anchalee Avihingsanon, MD, PhD $21,2601 Cipto Mangunkusumo General Hospital Substance use, Stigma, Depression and Disability Jakarta among Adults with HIV in Asia (S2D2) Nia Kurniati, MD $2,5141 PHILIPPINES TREAT Asia Pediatric HIV Observational TAHOD Low Intensity Transfer (TAHOD-LITE) Database (TApHOD) Asian Foundation for Tropical Medicine, Inc. 1 1 $8,000 $7,500 Muntinlupa City TREAT Asia HIV Observational Database (TAHOD) Evy Yunihastuti, MD, PhD Rossana Ditangco, MD Substance use, Stigma, Depression and Disability including NCD Data TREAT Asia HIV Observational Database (TAHOD) $24,3001 including NCD Data among Adults with HIV in Asia (S2D2) $23,0001 $6,500 Institute of HIV Research and Innovation (IHRI) Research Institute for Tropical Medicine Bangkok Muntinlupa City Nittaya Phanuphak-Pungpapong, MD, PhD JAPAN Rossana Ditangco, MD Amphetamine-type stimulant use, HIV incidence, Adolescent and Young Adult network of IeDEA and ART adherence among Thai MSM and National Center for Global Health and Medicine (AYANI) Study Site transgender women Tokyo $12,7181 $76,9021 Junko Tanuma, MD, PhD TREAT Asia HIV Observational Database (TAHOD) TREAT Asia HIV Observational Database (TAHOD) Anal HPV and risk for anal high-grade squamous $16,6401 including NCD Data intraepithelial lesion among Thai MSM with acute $22,3001 HIV infection $78,2681 MALAYSIA Mahidol University by Faculty of Medicine Siriraj SINGAPORE Hospital Penang Hospital Bangkok Georgetown Tan Tock Seng Hospital Kulkanya Chokephaibulkit, MD Revathy Nallusamy, MBBS Singapore TREAT Asia Pediatric HIV Observational TREAT Asia Pediatric HIV Observational Oon Tek Ng, MBBS, MRCP, MMed, MPH Database (TApHOD) Database (TApHOD) TREAT Asia HIV Observational Database (TAHOD) $7,5001 $5,3763 (funding awarded in 2020 for project $18,2001 years 14 & 15) Ramathibodi Hospital, Mahidol University Bangkok Sasisopin Kiertiburanakul, MD, MHS TAHOD Low Intensity Transfer (TAHOD-LITE) $10,0001

911 TREAT Asia HIV Observational Database (TAHOD) TREAT Asia Pediatric HIV Observational Database VIETNAM including NCD Data (TApHOD) $22,8001 $7,5001 Bach Mai Hospital Hanoi Chiang Mai University - Research Institute for Purple Haze Company Limited Do Duy Cuong, MD, PhD Health Sciences Bangkok TAHOD Low Intensity Transfer (TAHOD-LITE) Chiang Mai Tarandeep Anand $8,0001 Romanee Chaiwarith, MD, MHS The impact of online interventions on the HIV TREAT Asia HIV Observational Database (TAHOD) prevention/treatment cascade among MSM and TREAT Asia HIV Observational Database (TAHOD) including NCD Data TG Individuals including NCD Data $23,8001 $30,0001 $22,3001 Tavitiya Sudjaritruk, MD, ScM Little Birds Foundation National Hospital of Pediatrics Adolescent and Young Adult network of IeDEA Bangkok Hanoi (AYANI) Study Site Usanee Janngeon Nguyen Van Lam, MD, MSc $17,1821 Quality of life development for adolescents and Study on Pregnancy and Birth Outcomes among youth living with HIV Youth living with HIV in Asia Study on Pregnancy and Birth Outcomes among $10,0003 $1,2301 Youth living with HIV in Asia $1,8281 TREAT Asia Pediatric HIV Observational Database (TApHOD) TREAT Asia Pediatric HIV Observational Database USA $20,0001 (TApHOD) $15,0001 Johns Hopkins University National Hospital of Tropical Diseases Baltimore, MD Hanoi Chiangrai Prachanukroh Hospital Vidya Mave, MD, MPH & Amita Gupta, MD, MHA Pham Ngoc Thach, MD, PhD Chiang Rai A study to evaluate the markers of lung impairment TAHOD Low Intensity Transfer (TAHOD-LITE) Suwimon Khusuwan, MD in HIV-TB coinfected Indian adults $8,0001 TAHOD Low Intensity Transfer (TAHOD-LITE) $20,7911 $9,5001 TREAT Asia HIV Observational Database (TAHOD) Epidemiology of HIV/AIDS and associated including NCD Data TREAT Asia HIV Observational Database (TAHOD) comorbidities in a public antiretroviral treatment $22,3001 including NCD Data (ART) clinic in Pune, India $23,3001 $411,5711 (funding awarded in 2020 for project Children’s Hospital 1 years 14 & 15) Ho Chi Minh City Pradthana Ounchanum, MD Truong Huu Khanh, MD Study on Pregnancy and Birth Outcomes among IeDEA Sentinel Research Network (SRN)— TREAT Asia Pediatric HIV Observational Database Youth living with HIV in Asia Asia-Pacific (TApHOD) $5,4921 $23,5711 $20,0001 TREAT Asia Pediatric HIV Observational Database New Hope for Cambodian Children Children’s Hospital 2 (TApHOD) Killeen, TX Ho Chi Minh City $7,5001 John Tucker Do Chau Viet, MD HIV Education: New Hope for Cambodian Children Study on Pregnancy and Birth Outcomes among Srinagarind Hospital, Khon Kaen University $20,0243 Youth living with HIV in Asia Khon Kaen $1,4421 Pagakrong Lumbiganon, MD Columbia University Study on Pregnancy and Birth Outcomes among New York, NY TREAT Asia Pediatric HIV Observational Youth living with HIV in Asia Milton Wainberg, MD Database (TApHOD) $1,3941 Capacity development for HIV and mental health $20,0001 research in Asia (CHIMERA) $46,2502

1012 FINANCIALS

EXPENSES

Program $ 21,741,025 Fundraising 4,533,696 Management and general 2,357,534

Total $ 28,632,255

PROGRAM EXPENSES

Research $ 11,753,894 TREAT Asia 4,546,418 GMT Initiative 0 Public Policy 1,776,060 Public Information 3,664,653

Total $ 21,741,025

1113 FINANCIAL HIGHLIGHTS For the year ended September 30, 2020

Public Support and Revenue Public support $ 2,700,163 Special events 5,760,796 Planned giving 3,066,238 Government funding 6,657,827 Investment income and other revenue 2,608,564 Total public support and revenue $ 20,793,588

Expenses Research $ 11,753,894 TREAT Asia 4,546,418 GMT Initiative 0 Public Policy 1,776,060 Public Information 3,664,653 Total program services $ 21,741,025

Fundraising 4,533,696 Management and general 2,357,534 Total supporting services $ 6,891,230

Total expenses $ 28,632,255

Change in net assets (7,838,667) Net assets, beginning of year 49,484,561

Net assets, end of year $ 41,645,894

STATEMENT OF FINANCIAL POSITION

Assets Cash and investments $ 44,474,143 Pledges and receivables, net 4,479,604 Prepaid expenses and other assets 2,859,940 Furniture, equipment, and leasehold improvements, net 2,925,831 Total Assets $ 54,739,518

Liabilities Accounts payable and accrued expenses $ 2,489,524 CARES Act Paycheck Protection Program loan 1,643,364 Grants and fellowships payable, net 1,052,816 Deferred support and refundable advances 6,138,184 Other long-term liabilities 1,769,736 Total liabilities $ 13,093,624

Total net assets $ 41,645,894

Total liabilities and net assets $ 54,739,518

1214 Michael Lorber BOARD OF TRUSTEES Senior Vice President SCIENTIFIC ADVISORY Fiscal year 2020 Douglas Elliman Real Estate COMMITTEE New York, NY Edward Milstein Chairman of the Board* Co-Chairman *Adjunct Member William H. Roedy Milstein Brothers Capital Partners Chairman, MTV International (retired) New York, NY Mohamed Abdel-Mohsen, Ph.D.* London Assistant Professor United Kingdom Jeffrey Schoenfeld Vaccine & Immunotherapy Center *(10/01/2019-06/26/2020) Partner The Wistar Institute Head of Global Institutional Business Development Vice Chair* & Relationship Management Maria Luisa Alcaide, M.D.* Cindy Rachofsky Brown Brothers Harriman Associate Professor of Clinical Infectious Diseases Philanthropist New York, NY Miller School of Medicine Dallas, Texas University of Miami *(10/01/2019-06/26/2020) Alan Schwartz Executive Chairman Co-Chair* Richard Ambinder, M.D., Ph.D.* Guggenheim Partners, LLC T. Ryan Greenawalt Director, Division of Hematologic Malignancies New York, NY Managing Director Professor of Oncology Ramirez & Co. Mario Stevenson, Ph.D. School of Medicine Los Angeles, CA Professor of Medicine Johns Hopkins University *(07/01/2020-present) Chief, Division of Infectious Diseases Leonard M. Miller School of Medicine Jintanat Ananworanich, M.D., Ph.D. Co-Chair* University of Miami Associate Director for Therapeutics Research Kevin McClatchy Miami, FL US Military HIV Research Program Chairman of the Board The McClatchy Company Phill Wilson Patrick Arbuthnot* West Palm Beach, FL Founder and CEO, Black AIDS Institute (retired) Professor *(07/01/2020-present) Los Angeles, CA Director, Wits/SAMRC Antiviral Gene Therapy Research Unit Treasurer Faculty of Health Sciences Raymond F. Schinazi, PhD, DSc University of the Witwatersrand Frances Winship Walters Professor TRUSTEE EMERITUS Emory University School of Medicine Arthur J. Ammann, M.D. Robert Arduino, M.D.* Atlanta, GA President, Global Strategies for HIV Prevention Professor Secretary* Clinical Professor of Pediatrics Department of Medicine-Infectious Diseases Arlen H. Andelson University of California, San Francisco University of Texas Health Science Center at Senior Partner (retired) San Francisco, CA Houston Andelson & Andelson Los Angeles, CA Judith Auerbach, Ph.D.* *(deceased 10/26/2019) Professor of Medicine IN MEMORIAM School of Medicine Secretary* University of California, San Francisco Jay Ellis Mathilde Krim, Ph.D. Jay Ellis Foundation Founding Chairman Andrew Badley, M.D.* Los Angeles, CA Dame Elizabeth Taylor Professor of Medicine *(12/19/2019) Founding International Chairman Mayo Clinic College of Medicine Arlen H. Andelson Ben Berkhout, Ph.D.* Sheldon W. Andelson, Esq. Professor TRUSTEES Arnold W. Klein, M.D. Department of Medical Microbiology Mrs. Albert D. Lasker Academic Medical Center of the University of Danielle Alexandra Jonathan M. Mann, M.D., M.P.H. Amsterdam CEO, London Film and Television Group Maxine Mesinger Business Ambassador, Film, Television and Global Pauline Phillips Pascal Bessong, Ph.D.* Digital New Media Natasha Richardson Professor of Microbiology and Global Health Los Angeles, CA Allan Rosenfield, M.D. Chair of the HIV/AIDS & Global Health Research David Bohnett Peter Scott, Esq. Programme Chairman Wallace Sheft, C.P.A. University of Venda David Bohnett Foundation Tom Stoddard Beverly Hills, CA Joel D. Weisman, D.O. Daniel Blanco-Melo, Ph.D.* Department of Microbiology Donald Dye Icahn School of Medicine at Mount Sinai Chairman, Sky Lake Partners SPECIAL APPOINTMENT New York, NY Eli Bortiz, M.D., Ph.D.* Chief, Virus Persistence and Dynamics Section Aileen Getty Global Fundraising Chairman Milutin Gatsby (VPDS) The Aileen Getty Foundation National Institute of Allergy and Infectious Reno, NV Diseases Glenn Isaacson National Institutes of Health Vice Chairman Global Brokerage Alberto Bosque, Ph.D.* Cushman & Wakefield Assistant Professor New York, NY Department of Microbiology, Immunology, and Tropical Medicine The George Washington University

1315 Jason Brenchley, Ph.D.* Susanna Cunningham-Rundles, Ph.D. Homayoon Farzadegan, Ph.D. Senior Investigator Professor Emerita of Research Immunology Professor Immunopathogenesis Section Department of Pediatrics Department of Epidemiology National Institute of Allergy and Infectious Weill Cornell Medical College Johns Hopkins Bloomberg School of Public Health Diseases National Institutes of Health Richard Thomas D’Aquila, M.D. Maurizio Federico, Ph.D.* The Howard Taylor Ricketts Professor of Medicine Director Zabrina Brumme, Ph.D.* Division of Infectious Diseases National AIDS Center, Division of Pathogenesis of Professor, CIHR New Investigator, MSFHR Scholar Director, Northwestern HIV Translational Research Retroviruses Faculty of Health Sciences Center Istituto Superiore di Sanità Simon Fraser Unioversity Feinberg School of Medicine Northwestern University Daniel Fera, Ph.D.* Dennis R. Burton, Ph.D. Assistant Professor Professor Miles Davenport, D.Phil.* Department of Biochemistry Department of Immunology Professor Swarthmore College The Scripps Research Institute Centre for Vascular Research University of New South Wales Dianne M. Finkelstein, Ph.D. Salvatore T. Butera, D.V.M., Ph.D. Professor of Biostatistics Chief Science Officer Zeger Debyser, M.D., Ph.D.* Harvard School of Public Health Scripps CHAVI-ID Professor Director, Cancer Center Biostatistics The Scripps Research Institute Department of Molecular Medicine Massachusetts General Hospital Katholieke Universiteit Leuven Cheryl Cameron, Ph.D.* Andrés Finzi, Ph.D.* Assistant Professor Steven Deeks, M.D.* Associate Professor Case Western Reserve University Professor Department of Microbiology and Immunology School of Medicine Université de Montréal, Centre de Recherche du Edward Campbell, Ph.D. University of California, San Francisco CHUM Assistant Professor Department of Microbiology and Immunology Bruno De Geest, Ph.D. Gerald Herbert Friedland, M.D. School of Medicine Chemical Engineer Professor and Director Loyola University at Chicago Laboratory of Pharmaceutical Technology AIDS Care Program Ghent University Hospital Department of Internal Medicine Alex Carballo-Dieguez, Ph.D. Yale School of Medicine Co-Director and Senior Research Scientist Sherry Deren, Ph.D. HIV Center for Clinical and Behavioral Studies Co-Director Christina Gavegnano, Ph.D.* New York State Psychiatric Institute Center for Drug Use and HIV Research Assistant Professor Columbia University New York University College of Nursing Laboratory of Biochemical Pharmacology Department of Pediatrics Ann Chahroudi, M.D., Ph.D.* Roger Detels, M.D., M.S. Emory University Associate Director, Clinical Affairs Professor of Epidemiology Medical Scientist Training Program School of Public Health Howard E. Gendelman, M.D. Associate Professor, Infectious Disease University of California, Los Angeles Professor and Chair, Department of Pharmacology Department of Pediatrics and Experimental Neuroscience School of Medicine Carl W. Dieffenbach, Ph.D. Margaret R. Larson Professor of Internal Medicine Emory University Director and Infectious Diseases Division of AIDS (DAIDS) Director, Center for Neurodegenerative Disorders Nicolas Chomont, Ph.D.* National Institute of Allergy and Infectious University of Nebraska Medical Center Associate Research Professor Diseases Department of Microbiology and Immunology National Institutes of Health Sara Gianella Weibel, M.D.* Université de Montréal, Centre de Recherche du Assistant Professor of Medicine CHUM Dario Dilernia, Ph.D.* CFAR - Center for AIDS Research Research Assistant Professor Department of Medicine, Division of Infectious Amy Chung, Ph.D.* Pathology / Yerkes National Primate Research Diseases Laboratory Head Center at Emory Vaccine Center University of California, San Diego University of Melbourne Emory University Nancy L. Haigwood, Ph.D. David B. Clifford, M.D. Ivan D’Orso, Ph.D.* Director and Senior Scientist Professor Associate Professor Division of Pathobiology and Immunology Department of Neurology Department of Microbiology Oregon National Primate Research Center Washington University School of Medicine University of Texas Southwestern Oregon Health and Science University

C. Budd Colby, Ph.D. Daniel C. Douek, M.D., Ph.D. Andrew Henderson, Ph.D.* Principal Chief, Human Immunology Section Associate Professor Colby Biomedical Ventures Vaccine Research Center School of Medicine National Institute of Allergy and Infectious Boston University Grant Colfax, M.D. Diseases Director National Institutes of Health Alon Herschhorn, Ph.D.* Marin Health and Human Services Assistant Professor of Medicine San Rafael, California D. Peter Drotman, M.D., M.P.H. Division of Infectious Diseases and International Editor-in-Chief Medicine Deborah Jean Cotton, M.D., M.P.H. Emerging Infectious Diseases University of Minnesota Professor of Medicine Centers for Disease Control and Prevention Boston University School of Medicine Charles H. Hinkin, Ph.D. Anke A. Ehrhardt, Ph.D. Professor Bryan R. Cullen, Ph.D., D.Sc. Director Department of Psychiatry and Biobehavioral James B. Duke Professor Division of Gender, Sexuality, & Health Sciences Department of Molecular Genetics and Program for the Study of LGBT Health David Geffen School of Medicine Microbiology NYS Psychiatric Institute/Columbia University University of California, Los Angeles Director, Duke University Center for Virology Duke University Medical Center 1416 David Ho, M.D. Nathaniel R. Landau, Ph.D. Kenneth Hugh Mayer, M.D. Scientific Director, Chief Executive Officer Professor Infectious Disease Attending & Director of HIV Aaron Diamond AIDS Research Center Department of Microbiology Prevention Research New York University School of Medicine Beth Israel Deaconess Medical Center Ya-Chi Ho, M.D., Ph.D. * Professor of Medicine Assistant Professor of Microbial Pathogenesis Alan L. Landay, Ph.D. Harvard Medical School and Medicine Professor and Chairman Medical Research Director, Co-Chair Microbial Pathogenesis Department of Immunology and Microbiology The Fenway Institute/Fenway Health Yale University Rush-Presbyterian-St. Luke’s Medical Center Joseph M. McCune, M.D., Ph.D. Eric Hunter, Ph.D.* Michael Lederman, M.D. Professor of Medicine Professor Scott R. Inkley Professor of Medicine Department of Medicine Emory Vaccine Center Associate Director, Center for AIDS Research University of California, San Francisco Department of Pathology and Laboratory Medicine Case Western Reserve University School of Medicine Olivier Van Der Meeren, M.D.* Emory University Tun-Hou Lee, D.Sc. Research & Development Professor of Virology, Emeritus GlaxoSmithKline Thomas J. Hope, Ph.D. Department of Immunology and Infectious Professor Diseases Donna Mildvan, M.D. Department of Cell and Molecular Biology Harvard School of Public Health Chief, Division of Infectious Diseases Feinberg School of Medicine Department of Medicine Northwestern University Michael J. Leibowitz, M.D., Ph.D. Beth Israel Medical Center Professor, Medical Microbiology and Immunology Shiu-Lok Hu, Ph.D. University of California, Davis Hoi Ping Mok, Ph.D.* Professor Department of Medicine School of Pharmacy Robert J. Levine, M.D. University of Cambridge University of Washington Professor of Medicine Center for Interdisciplinary Research on AIDS Daniela Monaco, Ph.D.* Nuria Izquierdo-Useros, Ph.D.* Yale University Postdoctoral Fellow Associate Researcher Yerkes National Primate Research Center with AIDS Research Institute IrsiCaixa Judy Lieberman, M.D., Ph.D. Emory Vaccine Center Senior Investigator Emory University Moses Joloba, MBChB, MS, Ph.D.* Immune Disease Institute Associate Professor Professor of Pediatrics Godwin Nchinda, Ph.D.* College of Health Sciences, Department of Harvard Medical School Professor Medical Microbiology Senior Immunologist Makerere University Manuel Llano, M.D., Ph.D.* Head of Vaccinology/Biobanking Laboratory School of Medicine Assistant Professor Deputy Director General CIRCB Case Western Reserve University University of Texas at El Paso Chantal Biya International Reference Center for Research on the Prevention and Management R. Brad Jones, Ph.D.* Jeremy Luban, Ph.D.* of HIV/AIDS Assistant Professor of Immunology in Medicine David J. Freelander Chair in AIDS Research Graduate School of Medical Sciences Professor, Program in Molecular Medicine and Jay A. Nelson, Ph.D. Weill Medical College of Cornell University Biochemistry & Molecular Pharmacology Professor and Director Medical School Vaccine and Gene Therapy Institute Edward Kankaka, MBChB, MPH* University of Massachusetts Oregon Health and Science University Rakai Health Sciences Program H. Kim Lyerly, M.D. Douglas Nixon, M.D., Ph.D.* Jonathan Karn, Ph.D.* Professor in Surgery, Immunology, Pathology Professor of Immunology in Medicine Director George Barth Geller Chair of Cancer Research Weill Medical College of Cornell University Center for AIDS Research Director of the Center of Applied Therapeutics Case Western Reserve University Duke Cancer Institute David O’Connor, Ph.D.* Duke University Medical Center Professor Vineet KewalRamani, Ph.D. Department of Pathology and Laboratory Chief, Model Development Section Frank Maldarelli, M.D., Ph.D. Medicine HIV Drug Resistance Program Investigator University of Wisconsin-Madison National Cancer Institute HIV DRP Host-Virus Interaction Branch National Institutes of Health National Cancer Institute Nancy Padian, Ph.D., M.P.H. National Institutes of Health Adjunct Professor of Epidemiology Scott Kitchen, Ph.D. School of Public Health Assistant Professor of Medicine David M. Margolis, M.D. University of California, Berkeley Division of Hematology and Oncology Professor of Medicine, Microbiology and David Geffen School of Medicine Immunology, and Epidemiology Savita Pahwa, M.D. University of California, Los Angeles School of Medicine Professor of Microbiology and Immunology University of North Carolina at Chapel Hill Professor in Pediatrics and Medicine Richard Kornbluth, M.D., Ph.D. Director of the Miami Center for AIDS Research President and Chief Scientific Officer Martin H. Markowitz, M.D. University of Miami Leonard M. Miller School of Multimeric Biotherapeutics, Inc. Professor and Clinical Director Medicine Aaron Diamond AIDS Research Center Richard A. Koup, M.D. Tristram G. Parslow, M.D., Ph.D. Deputy Director, Vaccine Research Center Javier Martinez-Picado, Ph.D.* William Patterson Timmie Professor and Chair Chief, Immunology Laboratory Catalan Institute for Research and Advanced Department of Pathology and Laboratory National Institute of Allergy and Infectious Studies Research Professor Medicine Diseases AIDS Research Institute IrsiCaixa Emory University School of Medicine National Institutes of Health

17 Deborah Persaud, M.D.* Timothy Schacker, M.D.* Mario Stevenson, Ph.D. Professor Vice Dean for Research, Medical School Professor of Medicine School of Medicine Director, Program in HIV Medicine Chief, Division of Infectious Diseases Pediatric Infectious Disease Director, Clinical Translational Research Services, University of Miami Leonard M. Miller School Bloomberg School of Public Health Clinical and Translational Science Institute (CTSI) of Medicine Microbiology and Molecular Immunology Professor of Medicine, Division of Infectious Johns Hopkins University Diseases and International Medicine Lydie Trautmann, Eng.D., Ph.D.* University of Minnesota Chief Matija Peterlin, M.D. Cellular Immunology Section Professor of Medicine, Microbiology and Joshua Schiffer, M.D.* U.S. Military HIV Research Program Immunology Associate Member Department of Medicine Vaccine and Infectious Disease Division Sebastien Viel, PharmD, Ph.D.* University of California, San Francisco Associate Member Visiting Associate Professor Clinical Research Division Department of Pediatrics Christopher Peterson, Ph.D.* Fred Hutchinson Cancer Research Center Stanford University Staff Scientist Fred Hutchinson Cancer Research Center Frederick A. Schmitt, Ph.D. David Vlahov, Ph.D., R.N. Professor Professor of Nursing, Lynn Pulliam, Ph.D. Departments of Neurology, Psychiatry, and Epidemiology, and Biostatistics Professor Psychology and Behavioral Science University of California, San Francisco Department of Laboratory Medicine and Medicine Sanders Brown Center on Aging University of California, San Francisco University of Kentucky David J. Volsky, Ph.D. Veterans Affairs Medical Center Professor of Medicine and Pathology Gerald Schochetman, Ph.D. Icahn School of Medicine at Mount Sinai Reena Rajasuriar, Ph.D.* Senior Director Director of Molecular Virology Laboratory Pharmacy Lecturer Diagnostics Research Department of Medicine University of Malaya Abbott Laboratories Mount Sinai St. Luke’s and Roosevelt Hospitals

Christina Ramirez, Ph.D.* Sagi Shapira, Ph.D.* Angela Wahl, Ph.D.* Professor of Biostatistics Assistant Professor of Systems Biology Assistant Professor Fielding School of Public Health Department of Microbiology & Immunology Division of Infectious Diseases University of California, Los Angeles Columbia University UNC School of Medicine

Lee Ratner, M.D., Ph.D. Alex Sigal, Ph.D.* Misaki Wayengera, MBChB., MSc Immunology, Professor Group Leader, Max Planck Institute for Infection Ph.D.* Department of Medicine Biology Department of Pathology Washington University School of Medicine Africa Health Research Institute (AHRI) College of Health Sciences Makerere University Roger Keith Reeves, Ph.D.* Viviana Simon, M.D., Ph.D.* Associate Professor of Medicine Professor Steven S. Witkin, Ph.D. Harvard Medical School Department of Microbiology Professor of Immunology Ragon Institute of MGH, MIT, and Harvard Department of Medicine, Infectious Diseases Department of Obstetrics and Gynecology Director, Harvard CFAR Advanced Laboratory Icahn School of Medicine at Mount Sinai Weill Cornell Medical College Technologies Core Center for Virology and Vaccine Research Gail Skowron, M.D. Peter R. Wolfe, M.D. Beth Israel Deaconess Medical Center Professor of Medicine Associate Clinical Professor Boston University School of Medicine David Geffen School of Medicine Andrew Rice, Ph.D. University of California, Los Angeles Professor Natalia Soriano-Sarabia, Ph.D.* Sub-Investigator Department of Molecular Virology and Assistant Professor Ruane Clinical Research Microbiology Department Microbiology, Immunology and Baylor College of Medicine Tropical Medicine Kim Woodrow, Ph.D.* School of Medicine and Health Sciences Associate Professor Nadia Roan, Ph.D.* The George Washington University Department of Bioengineering Associate Professor University of Washington Department of Urology Leonidas Stamatatos, Ph.D. University of California, San Francisco Member Richard T. Wyatt, Ph.D. Fred Hutchinson Cancer Research Center Professor of Immunology Melissa Robbiani, Ph.D. Vaccine and Infectious Disease Division IAVI Center for Neutralizing Antibodies Senior Scientist and Director of Biomedical HIV Immunology and Vaccine Development Program The Scripps Research Institute Research Center for Biomedical Research Spyridon Stavrou, Ph.D.* Gert van Zyl, Ph.D.* Population Council Assistant Professor Associate Professor Department of Microbiology and Immunology Division of Medical Virology Mitchell Rosner, M.D.* Jacobs School of Medicine & Biomedical Deptartment of Pathology Henry B. Mulholland Professor of Medicine Sciences Faculty of Medicine & Health Sciences Chair, Department of Medicine State University of New York at Buffalo Stellenbosch University University of Virginia Kathryn Stephenson, M.D.* Ruth M. Ruprecht, M.D., Ph.D. Assistant Professor of Medicine Scientist, Department of Virology and Immunology Department of Medicine Southwest National Primate Research Center Beth Israel Deaconess Medical Center Director, Texas Biomed AIDS Research Program Texas Biomedical Research Institute

18 Katherine Luzuriaga, M.D. PROGRAM ADVISORY Professor, Molecular Medicine, Pediatrics MANAGEMENT GROUP COUNCIL and Medicine University of Massachusetts Medical School Worcester, MA Kevin Robert Frost Chief Executive Officer Mervyn F. Silverman, M.D., M.P.H. (Chairman) Kenneth H. Mayer, M.D. President Infectious Disease Attending and Director of HIV Anthony Ancona Mervyn F. Silverman Associates Prevention Research Vice President and Director, Human Resources Crockett, CA Beth Israel Deaconess Medical Center Susan J. Blumenthal, M.D., M.P.A. Senior Policy and Medical Advisor Judith D. Auerbach, Ph.D. Professor of Medicine Science and Policy Consultant, and Professor Harvard Medical School Kyle Clifford School of Medicine Vice President, Development University of California, San Francisco Medical Research Director and Co-Chair (June 2020—present) The Fenway Institute/Fenway Health David Bloom, Ph.D. Bradley Jensen Clarence James Gamble Professor of Economics Jeffrey L. Sturchio, Ph.D. Chief Financial Officer and Demography President and Chief Executive Officer Rowena Johnston, Ph.D. Department of Global Health and Population Rabin Martin, NYC Harvard T.H. Chan School of Public Health Vice President and Director, Research Boston, MA Visiting Scholar Jeffrey Laurence, M.D. The Institute for Applied Economics, Global Health Senior Scientific Consultant for Programs Tim Brown, Ph.D. and the Study of Business Enterprise Senior Fellow Johns Hopkins University Gregorio Millett, M.P.H. The East-West Center Vice President and Director, Public Policy Honolulu, HI Member Eric Muscatell The Council on Foreign Relations Daniel Douek, M.D., Ph.D. Vice President, Development (through May 2020) Chief, Human Immunology Section Phill Wilson Vaccine Research Center Member AnnMari Shannahan National Institute of Allergy and Infectious amfAR Board of Trustees Vice President, Public Information Diseases National Institutes of Health Founder and Chief Executive Officer (Retired) Annette Sohn, M.D. The Black AIDS Institute Vice President and Director, TREAT Asia Daria J. Hazuda, Ph.D. Los Angeles, CA Vice President, Scientific Affairs for Infectious Disease Merck & Company, Inc. West Point, PA

19 20 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax)

www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.